The Narrative Direction

Our strategic narrative runs on one spine: the move from the old way to the new way.

Arvind's story leads. It is the spine and the destination. Sue and Jen give that story arms and legs by answering the three questions every buyer is already asking. And Karina keeps us honest in how we say all of it.

That's the whole document. The rest is evidence, in their own words, for why we're recommending it.

The spine: old way to new way

The old way was right for its world. For decades, patient safety governed systems that followed rules. Protocols, sentinel-event reviews, just-culture frameworks. They worked because the things they governed behaved predictably.

The new way is built for the world we're actually in. AI is probabilistic. It learns from data, drifts over time, and shares the work with humans rather than waiting for their rules. The risks are the same (diagnostic errors, transitions of care, loop closures), but the causes have shifted: from manual, to EHR-rule-based, to AI and constantly-learning models. The category that names the destination is safe and reliable AI adoption. Reliability is deliberate ... as Arvind notes, it "appeals to the CFO," covering financial and operational stakes, not just clinical ones.

The destination never changes: high-reliability patient safety. What changes is how you reach it. You no longer reach it by writing the rule and waiting. You reach it in motion, one proven move at a time. And the word at the center of that destination is Karina's, which reframes what the buyer is really buying.

Why change?

Arvind's case: the game changed underneath the governance. The model a health system built to keep patients safe assumed systems follow rules. AI doesn't. It's probabilistic, it learns, it drifts, and it scales a single decision across every patient at once. Governing it with a rule-based playbook isn't safe, it's a blind spot. This is why "AI is an architecture, not a point solution" matters: you can't bolt safety onto one tool, you have to govern the whole environment.

The failure mode she names is precise: health systems are "struggling to fit this brand new technology into existing governance frameworks, and it's not a great fit." Square peg, round hole. Her recommendation became our line: stop force-fitting new AI problems into a safety program built before AI existed. We never say the old work was wrong. We say the world it was built for has changed.

Why now?

Jen's case: the urgency isn't theoretical, and the buyer doesn't need convincing the game changed. They're already living it.

What "now" actually looks like in a CIO's week, from Jen's live conversations:

• Epic flips on three AI features without asking.
• A vendor takes the radiologist to golf, and now they want a new tool.
• Microsoft is pressing on the Copilot rollout.
• The board wants ROI on the millions already spent.
• And the CIO is the 3 AM phone call when something breaks.

Her summary: "I'm living it, I'm breathing it. I'm on the battlefield." And the trap she flagged: "AI has killed the concept of a maturity scale. Most people are in all maturity lanes at once." The reason to move now is that the AI is already moving, with or without a plan. Sue's "AI Reach" sharpens the stakes: one bad consent flow doesn't harm one patient, it scales to 100,000.

Why Eisner Amper?

Sue's case, the sharpest differentiator we have: the gap isn't knowing what to do. Governance theory is everywhere. The gap is knowing how to operationalize it.

Eisner Amper's answer, in Sue's words: "We partner with you to get you where you need to be," not dropping the deck and wishing you luck. We design the workflow with you, build the feedback loop into the application, and stay through deployment and monitoring.

Arvind's reinforcement: the differentiator underneath the partnership is clinical integration. Platforms hand you software. We bring the rubric, the methodology (five pillars across the full lifecycle), and 20+ years of patient-safety work at Kaiser, CVS Health, the VA, Mass General Brigham, Mount Sinai, and Children's Hospital of Philadelphia. And from Jen: when there's no guidebook, the way you move safely is on proven ground, the patterns from peer systems who already made the move.

The weighting, stated plainly

Arvind leads. He owns the spine (old way to new way), he leads Why Change, and he anchors Why Eisner Amper with clinical integration and the methodology. Jen owns Why Now. Sue owns Why Eisner Amper. This matches how the team already operates: in their own intakes, both Sue and Jen deferred to Arvind on direction ("this is Arvind's practice, that's the message we should go with").

Karina: the tone, and the word at the center

Karina's role is different. She doesn't own one of the three questions ... she governs how we answer all of them. Three contributions, and the first is foundational.

She named what we're actually selling. The word "assurance" is Karina's: "The key word we always use is that assurance layer. They feel assured. Protected is too strong, but they have a path forward." Our entire spine rests on it. The buyer isn't buying governance, or a framework, or even safety in the abstract. They're buying the feeling of a path forward in a moment that feels pathless.

She set the guardrail. Never frame the buyer's existing work as antiquated. Tell a health system its protocols are outdated and it "screams you don't understand healthcare." In her words, "my stroke protocol keeps patients safe." We extend, we don't attack.

She surfaced the hidden objection. The buyer's first reaction is not "help me." It's "I'm good, I've got this." That changes how we open: we meet a confident buyer with respect, and let the specifics do the work. The confident buyer talks themselves into the room. We don't drag them.